Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  GlycoMimetics, Inc.    GLYC

GLYCOMIMETICS, INC.

(GLYC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
 SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations
Most relevant news about GLYCOMIMETICS, INC.
01/07GLYCOMIMETICS : Drug Candidate For Acute Myeloid Leukemia Gets Chinese Regulator..
MT
2020GLYCOMIMETICS : New Supportive Efficacy Data for GlycoMimetics' Rivipansel in Si..
BU
2020Roth Capital Adjusts GlycoMimetics' Price Target to $15 From $9, Reiterates B..
MT
2020GLYCOMIMETICS : Uproleselan in Combination with Venetoclax HMA Shown to Break Ch..
AQ
2020GLYCOMIMETICS : ' Uproleselan in Combination With Venetoclax/HMA Shown to Break ..
BU
2020GLYCOMIMETICS : to Present at Two Upcoming Virtual Healthcare Investor Conferenc..
AQ
2020GLYCOMIMETICS : to Present at Two Upcoming Virtual Healthcare Investor Conferenc..
BU
2020GLYCOMIMETICS : Reports Highlights and Financial Results for Third Quarter 2020
AQ
2020GLYCOMIMETICS : Reports Highlights and Financial Results for Third Quarter 2020
BU
2020GLYCOMIMETICS : 3Q Earnings Snapshot
AQ
2020GLYCOMIMETICS : Program Data to be Highlighted Via Three Oral Presentations and ..
BU
2020GLYCOMIMETICS : to Report Third Quarter Financial Results on November 6, 2020
AQ
2020GLYCOMIMETICS : to Report Third Quarter Financial Results on November 6, 2020
BU
2020GLYCOMIMETICS : New Pediatric and Secondary Endpoint Data from Rivipansel Phase ..
AQ
2020GLYCOMIMETICS : New Pediatric and Secondary Endpoint Data from Rivipansel Phase ..
BU
More most relevant news
All news about GLYCOMIMETICS, INC.
01/07GLYCOMIMETICS : Drug Candidate For Acute Myeloid Leukemia Gets Chinese Regulator..
MT
2020GLYCOMIMETICS : New Supportive Efficacy Data for GlycoMimetics' Rivipansel in Si..
BU
2020Roth Capital Adjusts GlycoMimetics' Price Target to $15 From $9, Reiterates B..
MT
2020GLYCOMIMETICS : Uproleselan in Combination with Venetoclax HMA Shown to Break Ch..
AQ
2020GLYCOMIMETICS : ' Uproleselan in Combination With Venetoclax/HMA Shown to Break ..
BU
2020GLYCOMIMETICS : to Present at Two Upcoming Virtual Healthcare Investor Conferenc..
AQ
2020GLYCOMIMETICS : to Present at Two Upcoming Virtual Healthcare Investor Conferenc..
BU
2020GLYCOMIMETICS : Reports Highlights and Financial Results for Third Quarter 2020
AQ
2020GLYCOMIMETICS INC : Results of Operations and Financial Condition, Financial Sta..
AQ
2020GLYCOMIMETICS : Reports Highlights and Financial Results for Third Quarter 2020
BU
More news
News in other languages on GLYCOMIMETICS, INC.
2017Les valeurs à suivre à Wall Street
Analyst Recommendations on GLYCOMIMETICS, INC.
2020Roth Capital Adjusts GlycoMimetics' Price Target to $15 From $9, Reiterates B..
MT
More recommendations
Press releases
2020GLYCOMIMETICS : New Supportive Efficacy Data for GlycoMimetics' Rivipansel in Si..
BU
2020GLYCOMIMETICS : Uproleselan in Combination with Venetoclax HMA Shown to Break Ch..
AQ
2020GLYCOMIMETICS : ' Uproleselan in Combination With Venetoclax/HMA Shown to Break ..
BU
2020GLYCOMIMETICS : to Present at Two Upcoming Virtual Healthcare Investor Conferenc..
AQ
2020GLYCOMIMETICS : to Present at Two Upcoming Virtual Healthcare Investor Conferenc..
BU
More press releases
Upcoming event on GLYCOMIMETICS, INC.